Press Releases
Cocrystal Pharma Commences Enrollment and Initiates Patient Dosing in Phase 2a Study Evaluating CC-31244 for the Treatment of HCV
Cocrystal Pharma Announces Inclusion in Russell Microcap® Index
Cocrystal Pharma Announces Nasdaq Closing Bell Ceremony
Cocrystal Pharma Reports 2018 First Quarter Financial Results and Provides Corporate Update
Cocrystal Pharma to Present at the Fred Hutch and Merck Infectious Disease Summit
COCRYSTAL PHARMA, INC., PRICES $8,000,000 COMMON STOCK OFFERING
Cocrystal Pharma Receives FDA Clearance to Initiate Phase 2a Clinical Study Evaluating CC-31244 for the Treatment of Hepatitis C Virus
Cocrystal Pharma Reports 2017 Financial Results and Provides Corporate Overview and Business Outlook
Cocrystal Pharma Announces Uplist to The Nasdaq Capital Market
